Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy.

Scientific reports - 5 Feb 2021

Yoshihama Sayuri, Cho Steven X, Yeung Jason, Pan Xuedong, Lizee Gregory, Konganti Kranti, Johnson Valen E, Kobayashi Koichi S

Abstract excerpt

Checkpoint blockade-mediated immunotherapy is emerging as an effective treatment modality for multiple cancer types. However, cancer cells frequently evade the immune system, compromising the effectiveness of immunotherapy. It is crucial to develop screening methods to identify the patients who would most benefit from these therapies because of the risk of the side effects and the high cost of treatment. Here we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Expression Regulation, Neoplastic
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Intracellular Signaling Peptides and Proteins

Share to Melanoma

Share to Mutation

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 33547395
DOI: 10.1038/s41598-021-82729-9
PMCID: PMC7865024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy.PMID 33547395Read ↗

NLRC5/MHC class I transactivator is a target for immune evasion in cancerSemantic proximity Read ↗

Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations.Semantic proximity Read ↗

CREB5 promotes immunotherapy resistance via tumor-intrinsic collagen matrix depositionSemantic proximity Read ↗

NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancersSemantic proximity Read ↗

Association of Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) Genetic Variants with Risk and Outcome of Cutaneous Melanoma.Semantic proximity Read ↗

Tumor <i>NLRP3</i> Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I ExpressionSemantic proximity Read ↗

A high‐throughput RNAi screen for detection of immune‐checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytesSemantic proximity Read ↗

Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival.Semantic proximity Read ↗

Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanomaSemantic proximity Read ↗

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.Semantic proximity Read ↗

Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.